Physician profile
Sabitha Eppanapally
NPI 1043449812
$1,571.49
in general payments reported to CMS, 2019-2025
25 companies · $182 in 2025
The $182 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $570 · 2020: $98.51 · 2021: $291 · 2022: $20.42 · 2023: $173 · 2024: $237 · 2025: $182.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $416 · Education: $175.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $416.43 |
| Education | $174.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $328.92 | 2019-2024 | Cresemba |
| Otsuka America Pharmaceutical, INC. | $242.98 | 2019-2025 | Jynarque, Voyxact |
| Pfizer INC. | $139.73 | 2019-2021 | |
| Aurinia Pharma U.S., INC. | $124.95 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $118.24 | 2019 | |
| Alkermes, INC. | $56.87 | 2019-2024 | Vivitrol |
| Alexion Pharmaceuticals, INC. | $50.87 | 2024-2025 | Ultomiris |
| Calliditas Therapeutics US INC. | $48.28 | 2025 | Tarpeyo |
| Travere Therapeutics, INC. | $41.08 | 2024-2025 | |
| Abbvie INC. | $40.47 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $40.18 | 2022-2023 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $36.04 | 2024 | Lifevest |
| Morphosys, US INC. | $34.52 | 2021 | |
| Eisai INC. | $32.94 | 2020 | |
| Vifor Pharma, INC. | $31.37 | 2019 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $27.84 | 2020 | |
| Baxter Healthcare | $25.42 | 2019 | |
| Dynavax Technologies Corporation | $23.02 | 2021 | |
| Genentech USA, INC. | $22.17 | 2025 | Gazyva |
| Merck Sharp & Dohme LLC | $20.34 | 2023 | Recarbrio, Zerbaxa |
| Bard Access Systems, INC. | $20.04 | 2019 | |
| Agios Pharmaceuticals, INC. | $17.93 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.51 | 2019 | |
| Allergan, INC. | $16.07 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $14.71 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sabitha Eppanapally listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.